Aprotinin administration in the pericardial cavity does not prevent platelet activation  by Maquelin, Kyra N. et al.
Objectives: Aprotinin is frequently administered systemically to patients
undergoing cardiopulmonary bypass to inhibit activation of platelets and
plasma protein systems and thus reduce postoperative blood loss. Two
reports on local aprotinin administration, that is, into the pericardial cavity,
also indicated improvement in postoperative blood loss, but the underlying
mechanism was not investigated. We previously reported the disappearance
of glycoprotein Ib from the platelet surface and the appearance of platelet-
derived microparticles in the pericardial cavity of patients undergoing car-
diopulmonary bypass as signs of platelet activation. Here, we investigated
whether such local aprotinin administration reduced platelet activation.
Methods: In a double-blind study, 6 patients received aprotinin (500,000
KIU) into the pericardial cavity during the operation and 7 patients received
a placebo. Platelet surface glycoprotein Ib expression, concentration of
microparticles, and concentration of complexes of platelets with leukocytes,
erythrocytes, or each other, were measured by flow cytometry.
Results: We confirmed the reduced glycoprotein Ib expression and the
increased concentration of microparticles in the pericardial cavity, as previ-
ously reported, and found no increased concentration of platelet complexes.
However, no differences between aprotinin and placebo treatments were
observed in these platelet activation parameters in the pericardial cavity or
the systemic circulation.
Conclusion: We conclude that administration of aprotinin into the pericardial
cavity during cardiopulmonary bypass and at concentrations similar to the
systemic application does not reduce platelet activation in that compartment
or the systemic circulation.  (J Thorac Cardiovasc Surg 2000;120:552-7)
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of the extracorporeal circuit. This contact was presumed
to activate several blood components, including the
coagulation system, the fibrinolytic system, the com-
plement system, and platelets.2 However, activation of
coagulation and fibrinolysis proved to be especially
pronounced in the pericardial cavity.3,4 In this compart-
ment, blood oozes from damaged vessels and exten-
sively contacts the damaged vessel wall and underlying
tissues. It accumulates in the pericardial cavity, from
which it is removed by suction and stored in a reservoir.
Periodically, the blood from the reservoir is returned
into the circulation of the patient. Inhibition of the acti-
vation processes in the pericardial cavity could be
advantageous. Tatar,5 O’Regan,6 and their associates
demonstrated a reduced postoperative blood loss when
aprotinin, a widely known medication to reduce postop-
erative blood loss if administered systemically, was
administered in the pericardial cavity just before the
E xcessive postoperative blood loss due to impairedhemostasis is one of the major complications of
heart surgery with cardiopulmonary bypass (CPB).1
Until recently, this was thought to be caused by the
extensive contact of the patients’ blood with the surface
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sternotomy was closed. However, the underlying mech-
anism was not investigated. We7 previously reported
that the surface expression of glycoprotein Ib (GPIb)—
an important adhesion receptor of the platelet—was
especially reduced in the pericardial cavity during
CPB. We8 also reported highly elevated numbers of
procoagulant, especially platelet-derived microparti-
cles, in the pericardial cavity.
The aim of the present double-blind placebo-con-
trolled study was to investigate whether the activation
of the platelets in the pericardial cavity or the systemic
circulation could be reduced by locally administering
aprotinin during the operation. The platelet activation
parameters included surface expression of GPIb, con-
centration of platelet-derived microparticles, and
platelet complexes as a sign of platelet activation plus
their ensuing interaction with other blood cells.9
Patients and methods
Clinical study. This study was approved by the local ethi-
cal committee. After their informed consent was obtained, 13
patients undergoing elective coronary artery bypass surgery
entered the study. One group of 6 patients received aprotinin
(50 mL containing 500,000 KIU, diluted with 50 mL saline
solution to facilitate gradual administration); the other group
of 7 patients received a placebo (saline solution) in the peri-
cardial cavity. During CPB, the solutions from the trial bot-
tles were sprinkled with a syringe into the pericardial cavity.
The sprinkling was started after the first blood sampling from
the pericardial cavity and continued up to the end of CPB,
just before administration of protamine sulfate. The random-
ized, double-blind study medication was supplied by Bayer
AG (Leverkusen, Germany). The code was broken after data
acquisition was completed. No patient was older than 85
years or had evidence of severe heart failure, renal or hepatic
dysfunction, or a bleeding diathesis. No patient was treated
with coumarin derivatives, aspirin, dipyridamole, or non-
steroidal anti-inflammatory agents within 5 days before the
operation. The study patients did not receive systemic antifi-
brinolytic agents or aprotinin during CPB. The aprotinin
dosage was based on the fact that aprotinin is administered
systemically at 2 × 106 KIU and the assumption that the sys-
temic circulating volume including the extracorporeal circuit
would be approximately 6 L versus the pericardial content of
500 to 1000 mL.
CPB and anesthesia. Anesthesia was induced and main-
tained with weight-related doses of fentanyl, sufentanil,
midazolam, or propofol and pancuronium. The extracorpore-
al circuit consisted of a Dideco D704 compact-flow system
oxygenator (Dideco SpA, Mirandola, Italy) and an S3 roller
pump (Stöckert, Munich, Germany). The priming of the
extracorporeal circuit contained lactated Ringer’s solution
(1.3 L), human albumin (200 mL 20% weight/volume), man-
nitol (100 mL 20% weight/volume), sodium hydrogen car-
bonate (50 mL 8.4% weight/volume), heparin (50 mg), and
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cefamandol (2 g). Each patient received dexamethasone (1
mg/kg). Volume was corrected with lactated Ringer’s solu-
tion. Heparin (300 IU/kg body weight) was given intra-
venously before cannulation of the aorta and repeated in a
dose of 50 mg whenever the activated clotting time
(Hemochron; International Technidyne Corp, Edison, NJ,
with kaolin used as an activator) was shorter than 480 sec-
onds. Pump flows ranged from 2.0 to 2.4 L · m–2 · min–1 dur-
ing hypothermia (28°C-32°C). Myocardial protection was
achieved with modified St Thomas’ Hospital solution infused
in the aortic root. After decannulation, heparin was neutral-
ized with protamine sulfate at 3 mg/kg body weight, that is,
in a 1:1 ratio of heparin to protamine sulfate.
Blood acquisition. All systemic blood samples were
drawn from the same central venous line. The blood samples
from the pericardial cavity were taken directly from the cav-
ity with a 10-mL syringe. Sampling points were after induc-
tion, before skin incision (sample point 1), 5 minutes after the
start of CPB (sample point 2), 10 minutes before release of
the aortic crossclamp, at the start of the last distal anastomo-
sis (sample point 3), and before protamine administration
(sample point 4). Systemic blood samples were taken at sam-
pling points 1 through 4 and samples from the pericardial
cavity at points 2 through 4. Blood samples were taken simul-
taneously at each sampling point.
Flow cytometric analysis. Whole blood flow cytometry
was performed essentially as described by us7 with some
modifications. Blood was collected in 0.32% trisodium cit-
rate (final concentration). Within 5 minutes after sampling, 5
µL aliquots of blood were added to tubes containing 35 µL of
N-2-hydroxyethylpiperazine-N-2-ethanesulfonic acid (HEPES)
buffer (sodium chloride, 137 mmol/L; potassium chloride,
2.7 mmol/L; magnesium chloride, 1.0 mmol/L; glucose, 5.6
mmol/L; HEPES, 20 mmol/L; albumin, 1 mg/mL; sodium
phosphate, 3.3 mmol/L; pH 7.4) and 5 µL anti-GPIb (final
concentration, 5 µg/mL). After 15 minutes of incubation at
room temperature in the dark, 5 µL of 10-fold diluted phyco-
erythrin-conjugated streptavidin was added. After another 15
minutes of incubation at room temperature in the dark, 2.5
mL of HEPES buffer containing 0.2% paraformaldehyde
(weight/volume) was added. No changes in the expression of
surface antigens occurred within 48 hours after fixation if
platelets were prepared according to this protocol
(Berckmans RJ, unpublished results). Anti-GPIb (CLB-
MB45) was obtained from the Central Laboratory of The
Netherlands Red Cross Blood Transfusion Service
(Amsterdam, The Netherlands). The antibody is directed
against GPIb-α. Anti-GPIb was biotinylated as described by
Hnatowich, Virzi, and Rusckowski.10 Phycoerythrin-conju-
gated streptavidin was obtained from Dakopatts (Glostrup,
Denmark).
The samples were analyzed in a FACScan flow cytometer
with Cell-Quest software (Becton Dickinson, San Jose,
Calif). Both forward and sideways scatter were set at loga-
rithmic gain. Per sample, a total of 5000 GPIb-positive events
(ie, platelets, platelet-derived microparticles, and platelet
complexes) were selected by the phycoerythrin-GPIb fluores-
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cence at 585 nm. Platelets (region 2), microparticles (region
1), and complexes (region 3) were identified by their light-
scattering characteristics. Platelet surface expression of GPIb
was first expressed as the mean fluorescence intensity of the
platelet population, which reflects the surface expression of
GPIb of the total platelet population. In a second analysis, the
percentage of platelets with decreased GPIb expression was
evaluated by setting a threshold arbitrarily at 10% with the
first systemic sample of each patient. Thus, subpopulations of
platelets with reduced GPIb expression may become appar-
ent.11 The absolute concentration of microparticles, that is,
corrected for hemodilution, in sample x was calculated by the
following formula: (Platelet count in blood sample x) ×
([Percent events in region 1 of blood sample x]/[Percent
events in region 2 of blood sample x]) × ([Immunoglobulin G
concentration in first systemic sample]/[Immunoglobulin G
concentration in sample x]). The concentration of platelet
complexes was similarly calculated on the basis of the num-
ber of events in region 3. No attempt was made to subdivide
those complexes into platelet-platelet, platelet-leukocyte, or
platelet-erythrocyte complexes.
Statistical analysis. Data were analyzed with SPSS for
Windows software, version 9.0 (SPSS, Inc, Chicago, Ill).
Differences between the systemic and the pericardial cavity
samples within the placebo and the aprotinin patient groups
were evaluated by GLM univariate multiple variation analy-
sis at an overall significance level of P = .05, followed by post
hoc analysis by means of the Scheffé test. The Mann-
Whitney U test was used to test differences between the
placebo and the aprotinin groups first at each individual sam-
ple point and subsequently between the systemic samples of
those groups at sample points 2 to 4. It was also used to test
between all pericardial samples at those sample points
(because the univariate analysis demonstrated no significant
differences between sample points 2 to 4 within the patient
groups).
Results
Clinical results. The clinical data are presented in
Table I. No significant differences were present between
the patient group treated with aprotinin and the placebo
group in age, number of distal anastomoses, CPB time,
crossclamp time, or blood loss within 6 hours after the
operation. We also did not observe a difference in the
number of patients receiving packed cells during and
after the operation (3 patients in each group) or the
number of packed cells transfused (7 in each group). No
complications occurred during or after the operation
except in 1 patient, in the aprotinin group, who required
re-exploration because of surgical bleeding.
Platelet GPIb expression. The results of the platelet
GPIb expression analyses are presented in Fig 1, A and
B. As we described previously, the platelet surface
expression of GPIb in the blood from the pericardial
cavity of the patients treated with placebo was signifi-
cantly less than that of the first systemic blood sample.
This was found both in the analysis of the mean GPIb
antigen expression of the platelet population (Fig 1, A:
systemic sample 1 vs pericardial cavity sample 2; 
P = .04) and in the analysis of the percentage of
platelets with a reduced surface GPIb expression (Fig 1,
B: systemic sample 1 vs pericardial cavity samples 2, 3,
and 4; all P < .001). Similar results were obtained in the
patients treated with aprotinin. The mean GPIb antigen
expression was reduced in pericardial cavity samples 2
and 3 (P = .004) compared with systemic sample 1 and
also systemic sample 2 (P = .05), and the percentage of
platelets with a reduced GPIb antigen expression was
increased in pericardial samples 2 and 3 compared with
systemic sample 1 (P = .001 and .003, respectively) and
also compared with systemic samples 2 (P = .014 and
.029, respectively) and 3 (P = .016 and .032, respective-
ly). There were no statistically significant differences in
mean platelet GPIb antigen expression between the
patient groups treated with aprotinin versus placebo at
any systemic or pericardial sample point. Also, the
pooling of all data within the 2 groups, pooling of the
data of the 4 systemic samples, or pooling of the 3 peri-
cardial cavity samples did not result in statistically sig-
nificant differences (P = .34, .18, and .59, respectively).
Differences also were not obtained with such analyses
of the percentages of platelets with reduced GPIb anti-
gen exposure (P = .93, .69, and .41, respectively).
Platelet microparticle formation. The results of the
platelet microparticle analyses are provided in Fig 1, C.
Both in the placebo-treated patient group and in the
aprotinin-treated group, we observed a significantly
increased concentration of platelet-derived microparti-
cles in pericardial cavity sample 4 versus all 4 systemic
samples (P < .001). In both patient groups, the concen-
tration of microparticles in pericardial cavity sample 4
was also increased compared with pericardial cavity
sample 2 (P < .001). Also, with the microparticle analy-
sis, we did not obtain statistically significant differ-
Table I. Clinical characteristics of the patients
Aprotinin Placebo
Age (y) 64 (55-70) 59 (49-75)
Sex (male/female) 6:0 6:1
Distal anastomosis (n) 5 (4-6) 4 (3-5)
CPB time (min) 121 (88-188) 101 (55-132)
Crossclamp time (min) 79 (57-126) 64 (34-91)
Blood loss 6 hours postop (mL)* 361 (140-900) 345 (160-500)
*The blood loss of the patient in the aprotinin group with a reoperation due to
surgical bleeding was not included in the analysis. There were no significant
differences between the 2 groups (Mann-Whitney U test, P > .05).
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ences in the comparisons of systemic or pericardial
cavity samples of placebo- versus aprotinin-treated
patient groups at any individual sample point (P > .05),
nor did we find this with the data in all systemic plus
pericardial samples or solely the systemic or pericardial
samples (P = .35, 0.49, and 0.68, respectively).
Platelet complexes. The results of the analyses of the
platelet complexes are presented in Fig 1, D. No statis-
tically significant differences were detected between
any systemic or pericardial cavity samples versus the
systemic sample at sample point 1 in the placebo- or
aprotinin-treated patient group. Also, the pooling of the
data as described above did not result in statistically
significant differences between the patient groups at a
single sample point (P > .05), in all systemic plus peri-
cardial samples, or in the systemic or pericardial sam-
ples separately (P = .38, .50, and .75, respectively).
Discussion
In the present study, we did not observe differences
in platelet activation between the aprotinin- and place-
bo-treated patient groups by means of the 3 markers
used: reduction of platelet surface GPIb expression,
microparticle formation, and platelet interaction with
each other or other cells. We did not investigate other
established parameters to detect platelet activation, for
example, surface expression of P-selectin, GP53, or
platelet-associated complement–1 binding, because
we7 previously demonstrated those parameters to be
unchanged during CPB in both the systemic circulation
and the pericardial cavity.
The clinical relevance of activation of various blood
systems in the pericardial cavity was already demon-
strated by de Haan and associates,12 who found
reduced postoperative blood loss if the pericardial
Fig 1.  Platelet activation analyses. A, The platelet surface expression of GPIb in the systemic circulation and the
pericardial cavity, expressed as the mean fluorescence intensity (MFI), as the mean surface antigen density. B, The
percentage of platelets with a reduced expression of GPIb, with the systemic sample at point 1 arbitrarily set at
10%. C, The concentration of platelet-derived microparticles. D, The concentration of platelet complexes, that is,
platelet-platelet, platelet-leukocyte, and platelet-erythrocyte complexes. The data are corrected for hemodilution.
Open bars represent the placebo group (n = 7) and hatched bars the aprotinin group (n = 6). Median and ranges
are provided. *P < .05, #P < .005, +P < .001.
A B
C D
content was not returned into the patient. However,
not returning the content from the pericardial cavity
should be balanced against a possible need for blood
transfusion, with all its disadvantages. An alternative
approach would be to inhibit the activation processes
in the pericardial cavity. A widely known medication
to prevent blood activation is aprotinin. Systemically
administered aprotinin reduces postoperative blood
loss.13 Tatar,5 O’Regan,6 and their colleagues demon-
strated a reduced postoperative blood loss when apro-
tinin was administered in the pericardial cavity just
before closure of the sternotomy. Bizzarri and
coworkers14 similarly treated the patients with local
aprotinin in addition to administering it systemically.
They thereby successfully reduced the postoperative
blood loss, but the studies cannot be compared with
ours because the local concentration of aprotinin may
then be much higher in their studies and will not
reduce the intraoperative activation of platelets and
plasma protein systems. We attempted to inhibit the
platelet activation at an early stage; that is, we admin-
istered aprotinin during the operation and at the site
presumed to have the highest activation state, the peri-
cardial cavity.7
The question could be raised whether the dosage of
aprotinin used in the present study was sufficient to
prevent platelet activation in the pericardial cavity. The
aprotinin dosage used (500,000 KIU) was based on the
fact that aprotinin is being administered systemically at
a dosage of 2 × 106 KIU and the assumption that the
systemic circulating volume including the extracorpo-
real circuit would be approximately 6 L versus the vol-
ume of the pericardial content of 500 mL to maximally
1 L. In vitro, the disappearance of GPIb from the
platelet surface can be induced by several stimuli, such
as thrombin and plasmin.15,16 Aprotinin inhibits plas-
min, kallikrein, and thrombin at an inhibition constant
(Ki) of 0.07 nmol/L, 36 nmol/L, and 61,000 nmol/L,
respectively. The concentrations used clinically are
thus sufficient to inhibit plasmin and kallikrein, but not
thrombin.17 In the present study, the 500,000 KIU, if
presumed to be present in 1 L of pericardial cavity
material, would correspond to 7700 nmol/L. This
would be insufficient to inhibit thrombin effectively. If
thrombin is indeed causing the platelet activation rep-
resented by the disappearance of GPIb from the platelet
surface plus microparticle formation, it may be won-
dered whether sufficiently high dosages of aprotinin
could then be obtained.
We did not find a difference in blood loss between
the aprotinin- and the placebo-treated patient groups.
The question could be raised whether the amount of
aprotinin used in the present study was sufficient to
expect an effect on blood loss. The aprotinin admin-
istered into the pericardial cavity provided a high
local concentration, as argued above. Virtually all of
it was subsequently given to the patient, because all
material from the pericardial cavity was collected
into the suction reservoir and returned to the heart-
lung machine, and the blood in the machine was
infused into the patient at the end of the operation.
On the one hand, the 0.5 × 106 KIU of aprotinin thus
administered is low compared with the 2 to 6 × 106
KIU regularly used systemically. On the other hand,
we administered the aprotinin intraoperatively and
thus facilitated continuous inhibition of the activation
processes. Tatar,5 O’Regan,6 and their associates
administered the same or twice this dosage of apro-
tinin at the end of the operation, respectively, and did
observe a reduced blood loss, even though the sys-
temic concentration was very low. Viewing these
results, we presume that local inhibition is more
effective than systemic administration and thus pro-
pose that the locally administered high aprotinin con-
centration is in itself sufficient. The small number of
patients in this study may preclude an effect on blood
loss. However, we aimed to study the effect of local
aprotinin administration on platelet activation and
not blood loss.
In conclusion, the administration of 500,000 KIU
aprotinin into the pericardial cavity during the CPB
procedure did not inhibit the activation of platelets in
this compartment, as measured by reduced surface
expression of the GPIb antigen, microparticle forma-
tion, and platelet complexes. A reduction in postopera-
tive blood loss or need for blood transfusion is there-
fore unlikely to be mediated by an effect on the platelet.
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